Simard Marc, Hill Lesley A, Lewis John G, Hammond Geoffrey L
Department of Cellular and Physiological Sciences (M.S., L.A.H., G.L.H.), Life Sciences Center, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3; and Steroid and Immunobiochemistry Laboratory (J.G.L.), Canterbury Health Laboratories, Christchurch 8011, New Zealand.
J Clin Endocrinol Metab. 2015 Jan;100(1):E129-39. doi: 10.1210/jc.2014-3130.
Corticosteroid-binding globulin (CBG) is encoded by SERPINA6. It is the major plasma binding protein of glucocorticoids and regulates plasma cortisol levels and bioavailability in humans. Several proteases target CBG and disrupt its steroid-binding properties. To date, most genetic deficiencies that alter plasma CBG levels or function have been identified in patients presenting with a variety of clinical conditions.
The objective of the study was to test 32 previously uncharacterized nonsynonymous, single-nucleotide polymorphisms in SERPINA6 for their ability to alter CBG production and/or function.
Human CBG mutants were produced in Chinese hamster ovary cells for ELISA, cortisol-binding activity measurements, and Western blotting as well as assays of their protease sensitivities.
Eight naturally occurring CBG mutants with abnormal production and/or function were identified. Cortisol-binding affinity was markedly reduced for CBG H14Q and CBG H89Y, moderately decreased for CBG I279F, and undetectable for CBG R260L. By contrast, CBG H14R exhibited a decreased cortisol-binding capacity. Comparison of CBG levels in cell extracts and media by Western blotting revealed that CBG I48N and CBG P246Q have secretion defects. Two mutants (CBG I179V and CBG I279F) displayed reduced rates of cortisol-binding activity loss after exposure to three different proteases (neutrophil elastase, chymotrypsin, and LasB produced by Pseudomonas aeruginosa).
Our data provide insight into how specific residues affect CBG secretion or function and illustrate the need to consider the various naturally occurring human CBG mutations in clinical evaluations of diseases associated with abnormalities in cortisol levels or activity.
皮质类固醇结合球蛋白(CBG)由SERPINA6编码。它是糖皮质激素的主要血浆结合蛋白,可调节人体血浆皮质醇水平和生物利用度。几种蛋白酶靶向CBG并破坏其类固醇结合特性。迄今为止,在患有各种临床病症的患者中已鉴定出大多数改变血浆CBG水平或功能的基因缺陷。
本研究的目的是测试SERPINA6中32个先前未鉴定的非同义单核苷酸多态性改变CBG产生和/或功能的能力。
在中国仓鼠卵巢细胞中产生人CBG突变体,用于ELISA、皮质醇结合活性测量、蛋白质印迹以及蛋白酶敏感性测定。
鉴定出8种产生和/或功能异常的天然存在的CBG突变体。CBG H14Q和CBG H89Y的皮质醇结合亲和力显著降低,CBG I279F中度降低,CBG R260L无法检测到。相比之下,CBG H14R的皮质醇结合能力降低。通过蛋白质印迹比较细胞提取物和培养基中的CBG水平,发现CBG I48N和CBG P246Q存在分泌缺陷。两种突变体(CBG I179V和CBG I279F)在暴露于三种不同的蛋白酶(中性粒细胞弹性蛋白酶、胰凝乳蛋白酶和铜绿假单胞菌产生的LasB)后,皮质醇结合活性丧失率降低。
我们的数据提供了关于特定残基如何影响CBG分泌或功能的见解,并说明了在与皮质醇水平或活性异常相关的疾病的临床评估中需要考虑各种天然存在的人类CBG突变。